Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Leukemia|January 12, 2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual diseaseG A Horne, J Stobo, C Kelly, et al.
British Journal of Haematology|July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patientsPhilippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Journal of the National Cancer Institute|November 23, 2017
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy InhibitionRebecca Mitchell, Lisa E M Hopcroft, Pablo Baquero, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Hemasphere|August 4, 2026
Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC studyBenjamin Podvin, Olivier Nibourel, Sandrine Hayette, et al.
The Lancet. Haematology|February 10, 2025
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trialJorge E Cortes, Dong-Wook Kim, Tapan Saikia, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
British Journal of Haematology|October 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study)Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, et al.
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
Pageof 12